InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

InflaRx N.V.NASDAQ: IFRX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was €0, compared with €9.29K a year earlier. Trailing-twelve-month cost of revenue was €7.26M.

Context

  • Cost of revenue amounted to 24777.9% of revenue in FY2025, up 22777.2 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near €0 or moves back toward the trailing-twelve-month quarterly average of €1.81M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0-100.0% QoQ
Last fiscal yearDec 2025
€7.27M+119.1% YoY
LTMMar 2026
€7.26M+133.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+119.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

EUR · from the income statement

Latest · FY2025
7.27M EUR
Year-over-year change
+119.1%

Cost of Revenue vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +133.7% is the highest of 5, against a peer median of -32.4%.
  • Cost of revenue amounts to 24746.3% of revenue for IFRX, versus a peer median of 91.6%.
IFRX Competitors
Cost of Revenue for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATYRaTyr Pharma, Inc.LTM Mar 2026$22.52M USD+84.2%-2.9%11854.7%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M USD-28.6%-4.0%1.3%
IMAImageneBio IncLTM Mar 2026$780K USD-95.0%-74.8%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$666K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$40.17K USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
Peer median (excluding IFRX) —-32.4%-4.0%91.6%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.